Paul Wallace, PhD
Dr. Paul K. Wallace joined the staff of Roswell Park Cancer Institute (RPCI) in 2003, as Director of the Flow and Image Cytometry Resource. He is an Associate Professor in the Department of Cancer Prevention and Pathology and a Member of the Immunology Program. He is also an Associate Professor in the Departments of Pathology and of Biotechnical and Clinical Laboratory Sciences, University at Buffalo. (SUNY)
He earned his doctoral degree in Immunology at the Medical College of Pennsylvania (Drexel University), Philadelphia, PA, and completed a postdoctoral fellowship in Immunology at Dartmouth Medical School, Hanover, NH in 1996 and remained at Dartmouth as an Assistant Professor until joining Roswell Park.
Dr. Wallace is an active member of the International Society for Analytical Cytometry (ISAC) and the International Clinical Cytometry Society. He has authored or co-authored more than 85 peer reviewed journal articles or book chapters and has over 190 Abstracts. He is also Director of the Annual Clinical Flow Cytometry course.
Under Dr. Wallace’s direction the Flow and Image Cytometry Resource at Roswell Park is divided into clinical and research activities. The Clinical Flow Cytometry laboratory is a CLIA certified facility offering a comprehensive menu of diagnostic procedures and support for clinical trials. Dr. Wallace’s clinical responsibilities focus on the diagnosis and monitoring of hematological disorders. Recent and ongoing research activities in the clinical laboratory include the implementation of eight color diagnostic panels, identification and function of regulatory T cells subsets and automation through robotics of our staining procedures. The clinical flow cytometry laboratory has an internationally recognized educational program offering an advanced technical internship and a PhD with emphasis in clinical flow cytometry.
The Research Core facility services and maintains for investigators at Roswell Park and throughout the Greater Buffalo area a number of flow and image cytometers. We daily perform four to eight color immunophenotyping and are equipped to simultaneously collect, analyze and sort samples stained with up to 18 fluorochromes. Because of Dr. Wallace’s research interests in immune monitoring, particularly related to quantifying the development of different immune responses in cancer patients, we routinely perform cell proliferation, phagocytosis, multimer and intracellular cytokine assays.
Dr. Wallace’s active research interests include the development of a number of novel lipophilic dyes expanding the available spectrum of choices to track cells in vivo and in vitro. As the demand for multiparametric experiments intensifies, it has become increasingly important to utilize a broader range of cell tracking reagents to optimize the measurement of fluorescence signals and to provide flexibility in the use of commercially available fluorochrome - antibody combinations. Thus far, he has successfully designed lipophilic dyes with fluorescence emissions in the violet, far-red and near infrared wavelength regions. These are being used to monitor immune response and function using flow cytometric based cytotoxic, phagocytic, and proliferation assays. A second major area of researchis focused on investigating an immunotherapeutic modality for the treatment of cancer. We believe that the immune system is well equipped to address and remove cells that express modified self antigens, and may thus serve as an effective, systemic therapy provided that tolerance to tumor antigen can be broken. He is using antibody vehicles to target tumor antigen to dendritic cells (DCs). These antibodies specificity target pattern recognition molecule found on DCs. Our data demonstrates that after fusing tumor antigen to these targeting antibodies, these constructs can be exploited to deliver antigen much more efficiently to DCs. Subsequently, we are able to measure robust Class I and II-driven responses.